Your browser doesn't support javascript.
loading
Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Xiong, Yan; Greschik, Holger; Johansson, Catrine; Seifert, Ludwig; Gamble, Vicki; Park, Kwang-Su; Fagan, Vincent; Li, Fengling; Chau, Irene; Vedadi, Masoud; Arrowsmith, Cheryl H; Brennan, Paul; Fedorov, Oleg; Jung, Manfred; Farnie, Gillian; Liu, Jing; Oppermann, Udo; Schüle, Roland; Jin, Jian.
Afiliación
  • Xiong Y; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Greschik H; Department of Urology and Center for Clinical Research, University Freiburg Medical Center, Freiburg 79106, Germany.
  • Johansson C; Structural Genomics Consortium, Botnar Research Center, NIHR Oxford BRU, University of Oxford, Oxford OX3 7LD, U.K.
  • Seifert L; Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg 79104, Germany.
  • Gamble V; Structural Genomics Consortium, Botnar Research Center, NIHR Oxford BRU, University of Oxford, Oxford OX3 7LD, U.K.
  • Park KS; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Fagan V; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.
  • Li F; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Chau I; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Vedadi M; Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.
  • Arrowsmith CH; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
  • Brennan P; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Fedorov O; Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Jung M; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.
  • Farnie G; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.
  • Liu J; Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg 79104, Germany.
  • Oppermann U; German Cancer Research Centre (DKFZ), Heidelberg 69120, Germany.
  • Schüle R; German Cancer Consortium (DKTK), Freiburg 79104, Germany.
  • Jin J; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, U.K.
J Med Chem ; 67(7): 5837-5853, 2024 Apr 11.
Article en En | MEDLINE | ID: mdl-38533580
ABSTRACT
The methyl-lysine reader protein SPIN1 plays important roles in various human diseases. However, targeting methyl-lysine reader proteins has been challenging. Very few cellularly active SPIN1 inhibitors have been developed. We previously reported that our G9a/GLP inhibitor UNC0638 weakly inhibited SPIN1. Here, we present our comprehensive structure-activity relationship study that led to the discovery of compound 11, a dual SPIN1 and G9a/GLP inhibitor, and compound 18 (MS8535), a SPIN1 selective inhibitor. We solved the cocrystal structure of SPIN1 in complex with 11, confirming that 11 occupied one of the three Tudor domains. Importantly, 18 displayed high selectivity for SPIN1 over 38 epigenetic targets, including G9a/GLP, and concentration dependently disrupted the interactions of SPIN1 and H3 in cells. Furthermore, 18 was bioavailable in mice. We also developed 19 (MS8535N), which was inactive against SPIN1, as a negative control of 18. Collectively, these compounds are useful chemical tools to study biological functions of SPIN1.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dominio Tudor / Lisina Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dominio Tudor / Lisina Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos